Nitric oxide-releasing nanoparticles reveals viable skin infection treatment

02-Aug-2017 - George Washington University (GW) researchers have found that topically applied nitric oxide-releasing nanoparticles (NO-np) are a viable treatment for deep fungal infections of the skin caused by dermatophytes, for which the current standard of care is treatment with systemic ...

NicOx submits naproxcinod MAA to the EMEA

23-Dec-2009 - NicOx S.A. announced that a Marketing Authorization Application (MAA) for naproxcinod has been submitted to the European Medicines Agency (EMEA) through the centralized procedure, seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). This follows the ...

NicOx announces NCX 6560 meets primary and secondary objectives in first-in-man study

16-Nov-2009 - NicOx S.A. announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected ...

NicOx acquires Nitromed’s NO-donating patents

24-Apr-2009 - NicOx S.A. announced it has agreed to purchase Nitromed’s unlicensed patent estate covering nitric oxide-donating compounds. According to the company, this acquisition gives NicOx by far the strongest intellectual property position on this technology worldwide, including a large number of new ...

NicOx initiates proof-of-principle clinical study for NCX 6560

First-in-man study for an innovative investigational drug, representing a global therapeutic approach for reduction of cardiovascular risk

20-Mar-2009 - NicOx S.A. announced the initiation of clinical development for NCX 6560, a novel, nitric oxide-donating compound which could become an improved investigational drug for serious cardiovascular diseases. The first-in-man study will enroll both healthy male volunteers and those with abnormally ...

Third pivotal phase 3 study for NicOx’ naproxcinod shows positive efficacy, safety and blood pressure results

25-Nov-2008 - NicOx S.A. announced that the third pivotal phase 3 study for naproxcinod in patients with osteoarthritis (OA) of the hip showed a highly statistically significant result ...

NicOx’ naproxcinod shows highly significant reduction in daytime blood pressure versus naproxen

New analysis of the 104 ABPM study presented at the American Heart Association

13-Nov-2008 - NicOx S.A. announced that a new analysis of the data from the 104 Ambulatory Blood Pressure Monitoring (ABPM) study for naproxcinod was presented at the American Heart Association Scientific Sessions 2008, in New Orleans, USA. This ABPM pilot study in hypertensive volunteers was designed to ...

NicOx announces initiation of first phase 1 study of investigational nitric oxide-donating agent in hypertensive patients

14-May-2008 - NicOx S.A. announced that Merck & Co., Inc. has initiated the first in a series of planned clinical studies, in mild to moderate hypertensive patients, under the companies' collaborative agreement to develop new nitric oxide-donating antihypertensive agents using NicOx' proprietary technology. ...

NicOx announces U.S. phase 2a results for PF-03187207 and gives an update on continuing NO-prostaglandin program

07-May-2008 - NicOx S.A. announced the results of a U.S. phase 2 study, conducted by its partner Pfizer Inc, which compared the safety and efficacy of various doses of PF-03187207 to Xalatan® (latanoprost) 0.005% in patients with primary open-angle glaucoma and ocular hypertension. The higher doses of ...

NicOx signs agreement for the commercial manufacture of naproxcinod drug substance

20-Mar-2008 - NicOx S.A. announced it has signed an agreement with the fine chemical company Archimica, for the commercial manufacturing and supply of naproxcinod drug substance (or active pharmaceutical ingredient, API). Naproxcinod is NicOx' lead investigational product and the first compound in the ...